Oxidative Stress Assays Market
Oxidative Stress Assays Market Analysis by Antioxidant Capacity Assays, Ascorbic Acid Assays, Glutathione Assays, and Others from 2023 to 2033
Analysis of Oxidative Stress Assays Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Oxidative Stress Assays Market Outlook (2023 to 2033)
Progressing at a CAGR of 9%, the global oxidative stress assays market is valued at US$ 1.05 billion in 2023 and is this expected to reach US$ 2.49 billion by the end of 2033. This can be primarily attributed to the rapidly rising demand for oxidative stress assays from pharma and biotech companies.
Reactive oxygen species (ROS) generation rises under conditions of oxidative stress, and when antioxidant defences within cells become less effective. High metabolism or a stress response cause cells to produce ROS. Antioxidant glutathione (GSH) is utilized to lessen ROS-caused harm. The presence of oxidative stress markers & reagents in cells is detected and screened using oxidative stress assays.
Glutathione can be measured in both its reduced and oxidised levels using a GSH/GSSG-Glo assay. The test is created by converting a Glutathione S-transferase enzyme's Luciferin-NT GSH probe into Luciferin. The firefly luciferase reaction that results from the production of luciferin in this way generates a luminous signal that is proportional to the level of GSH present in the cells.
As different ROS in the cells are transformed into hydrogen peroxide (H2O2), the ROS with the longest half-life, a measurement of H2O2 levels can also serve as a proxy for ROS levels. Using a substrate that directly reacts with H2O2, the ROS-Glo assay generates a luminous signal that is proportional to the levels of H2O2 present.
Oxidative stress assay tests are segmented into antioxidant capacity assays, ascorbic acid assays, glutathione assays, cell-based exogenous antioxidant assays, indirect assays, lipid-based assays, nucleic acid-based assays, protein-based assays, enzyme-based assays, and reactive oxygen species-based assays. Indirect signs of oxidative stress include DNA/RNA damage, protein oxidation/nitration, and lipid peroxidation.
The most widely utilized DNA damage indicator is probably 8-hydroxydeoxyguanosine. Malondialdehyde (MDA), a lipid marker for oxidative stress which is also most commonly employed, is produced when polyunsaturated fatty acids are peroxidized and measured using the thiobarbituric acid reactive substance (TBARS) assay. Protein oxidative damage leads to protein nitration (3-nitrotyrosines). Advanced oxidation protein products (AOPP), which may be detected, using conventional assays, can also be produced as a result of ROS.
Based on offerings, oxidative stress assays are classified into consumables, instruments, and services. Global demand for consumables is expected to increase at a CAGR of 9.5% from 2023 to 2033. Clinical advancements, growing usage in the biotechnological and contract research organizations (CRO) sectors, and the recurring needs for consumables relative to instruments are some of the factors driving overall market growth.
Report Attributes |
Details |
|
Oxidative Stress Assays Market Size (2023E) |
US$ 1.05 Billion |
|
Forecasted Market Value (2033F) |
US$ 2.49 Billion |
|
Global Market Growth Rate (2023 to 2033) |
9% CAGR |
|
China Market Growth Rate (2023 to 2033) |
8% CAGR |
|
Japan Market Growth Rate (2023 to 2033) |
8% CAGR |
|
Germany Market Growth Rate (2023 to 2033) |
6.5% CAGR |
|
Canada Market Growth Rate (2023 to 2033) |
7% CAGR |
|
Key Companies Profiled |
|
What is Positively Influencing the Demand for Oxidative Stress Assays?
“Increasing Global Risk of Infectious Diseases”
Growing research and development activities in the medical sector across the world are boosting the demand for oxidative stress assays. The oxidative stress assays are expected to be beneficial for the detection of infectious diseases.
- According to a study conducted in May 2021 and published in the journal ‘Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants’, oxidative stress and inflammation are linked processes that influence both the course of the illness and how well it responds to treatment by interfering with a variety of signalling pathways.
- Given the particular conditions necessary for the conformational modifications that guarantee the binding and introduction of a virus into the host cell, the redox status of a host cell is a significant determinant in viral entry.
Such studies show the value of oxidative stress tests in monitoring COVID-19 progression, which subsequently is boosting the sales of oxidative stress assays.
“Rising Prevalence of Chronic Disorders”
One of the main factors anticipated to propel the growth of the market for oxidative stress assays is the quick development of the biopharmaceutical and biotechnology sectors. Another key factor is the increasing number of cases related to chronic diseases. Due to the enhanced efficacy and precision of the results and the fact that chronic diseases lead to an imbalance in oxidant and antioxidant levels, the growing incidences of chronic disorders are boosting the need for oxidative stress tests.
- 6 out of 10 adults in the United States are living with chronic illness, and 4 out of 10 adults are experiencing two or more disorders, according to the Centers for Disease Control and Prevention's (CDC) May 2022 report.
- The September 2021 publication of the paper ‘Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy’ revealed that when concentrations rose, reactive oxygen species (ROS) paradoxically influence cancer progression, whether inducing carcinogenesis or promoting the growth of cancer cells at medium levels of ROS or killing cancer cells at high levels of ROS.
- As a result, ROS can be seen as a desirable target for the treatment of cancer. It also stated that one of the potential approaches to address existing cancer treatment difficulties may be the utilization of medications that have been repurposed based on ROS.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Obstacles Need to Be Overcome by Oxidative Stress Assay Producers?
“High Cost of Advanced Instruments”
For oxidative stress tests, label-free detection and high-content screening (HCS technologies have numerous advantages over traditional ones. These technologies cost more because they come with more sophisticated features and functionality.
A confocal microscope can cost up to US$ 250,000 when used in HCS. Pharma & biotech companies with limited R&D resources therefore cannot afford advanced devices due to their high cost. Thus, the capital expense of pharmaceutical businesses rises dramatically due to the high demand for devices with advanced technologies.
Academic research labs also find it challenging to invest in such systems because of their tighter budgets. Therefore, the high expenses linked to improved technologies could impede the growth of the oxidative stress assays market.
Country-wise Analysis
What is Driving the Sales of Oxidative Stress Assays in the United States?
“Presence of Major Pharma & Biotech Companies”
The United States currently holds a dominating position in the North American market. This can be due to the rapidly rising demand for oxidative stress assays from biopharma and biotech companies.
Furthermore, it is anticipated that the rising use of technologically sophisticated devices and the availability of skilled experts will boost the growth of the oxidative stress assays market in the United States. The oxidative stress tests are essential to the production of biopharmaceuticals, thus, the rising rate of new product launches by biopharmaceuticals is boosting sales growth.
Which Factors are Expected to Push Demand for Oxidative Stress Assays in Germany?
“Rising Prevalence of Cardiovascular Disorders in the Country”
Increasing cases of cardiovascular disorders and the rising preference for minimally-invasive procedures in Germany are expected to boost the demand for oxidative stress assays. Several market players are also focusing on producing advanced assay solutions. According to Fact.MR, a market research and competitive intelligence provider, sales of oxidative stress assays in Germany are predicted to rise at a CAGR of 6.5% during the next 10 years.
- According to estimates by the German Heart Surgery Report 2021, 161,261 cardiac-related treatments were carried out in Germany in 2021.
How are Sales of Oxidative Stress Assays Progressing in Japan?
“Rising Cases of Diabetes in Japan”
The market for oxidative stress assays in Japan is evolving at a high CAGR of 8% from 2023 to 2033. The increasing prevalence of diabetes is generating potential growth opportunities in the oxidative stress assays market in Japan.
Type 2 diabetes is caused due to an unhealthy lifestyle, which causes the development of innate resistance to insulin, whereas Type 1 diabetes is brought on by an immune system failure. As a result, Type 1 diabetes is known as insulin-required diabetes, and Type 2 diabetes is known as insulin-dependent diabetes.
A significant rate of the elderly population in the world is found in Japan, which increases the chances of developing type 2 diabetes. Thus, the rapidly rising rate of the senior population is increasing the cases of diabetes, which further increases the demand for oxidative stress assays for monitoring and diagnosis of diabetes.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Analysis
Why are Pharma & Biotech Companies Big Users of Oxidative Stress Assays?
“Increasing Use of Oxidative Stress Assays in Monitoring & Management of New Medicines”
Pharma & Biotech companies hold a dominating share of the global oxidative stress assays market. The oxidative stress assays are crucial for the development of pharma and biotech products, the COVID-19 pandemic has significantly increased the demand for oxidative stress assay products.
Since oxidative stress tests are commonly utilized in the product development process, the surge in research and development spending in pharmaceutical and biotech companies is anticipated to enhance sales growth.
- According to information from the Organization for Economic Development and Co-operation (OECD) published in 2021, China's research and development investment intensity in the pharma and biotech sector was 2.1% to 2.2% higher than the previous year, while in the United States, it had crossed the 3% mark. The report also noted that spending on research and development increased more slowly in Europe, by 2.1 percent.
The launch of novel medicines and the regulatory bodies' clearance of existing products are also some of the factors aiding sales growth.
- For those researchers looking into the mechanism of oxidative stress, AMSBIO, in June 2022, enhanced their selection of biomarkers, antibodies, and assay kits connected to antioxidants, free radicals (ROS and RNS), and non-radical reactive derivatives (or oxidants).
Because they significantly use oxidative stress assay products for the research and development of newer illness diagnoses, the pharmaceutical and biotechnology industry sector is anticipated to hold the majority of the market share in light of these reasons.
Competitive Landscape
Key players in the oxidative stress assays market are focusing on the advancement of assay products. To maintain their market position and earn more, some of the leading companies are concentrating on regional expansion, local supply, changes in pricing trends, product standards, and more.
- In July 2021, Immuchrom GmbH and Ilex Life Sciences inked a collaboration agreement for the commercialization of gastrointestinal biomarker assays in North America. Immuchrom is a German researcher and manufacturer of photometric assays, immunoassays, and HPLC applications with a focus on oxidative stress, gastrointestinal disease, cardiovascular disease, and calcium and bone metabolism.
- The Photo-oxidation Resistant DCFH-DA ROS Assay Kit was introduced in June 2022 by Dojindo, in Japan.
- FusionPlex Dx and LiquidPlex Dx were launched by Invitae in February 2022 in Europe. FusionPlex Dx is designed to be utilized as a CDx to help identify patients with NSCLC who have ROS proto-oncogene 1 (ROS1) fusions and other conditions that might improve from targeted therapy.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Oxidative Stress Assays Industry Research
-
By Offering :
- Consumables
- Instruments
- Services
-
By Test Type :
- Antioxidant Capacity Assays
- Ascorbic Acid Assays
- Glutathione Assays
- Cell-based Exogenous Antioxidant Assays
- Indirect Assays
- Lipid-based Assays
- Nucleic Acid-based Assays
- Protein-based Assays
- Enzyme-based Assays
- Reactive Oxygen Species-based Assays
-
By Technology :
- ELISA
- Chromatography
- Flow Cytometry
- Microscopy,
- High-content Screening
- Label-free Detection
-
By Disease :
- Cardiovascular Diseases
- Diabetes
- Respiratory Diseases
- Cancer
- Asthma
-
By End User :
- Pharma & Biotech Companies
- Academic Research Institutes
- Clinical Laboratories
- Contract Research Organizations
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Rise in Expenditure 4.1.2. Increased Per Capita Expenditure 4.2. Forecast Factors - Relevance & Impact 4.2.1. Product in Pipeline 4.2.2. Regulatory Scenario 4.2.3. Mergers and Acquisitions 4.2.4. Collaborative Agreements 4.2.5. Value Chain 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 4.4. COVID19 Crisis Analysis 4.4.1. Current COVID19 Statistics and Probable Future Impact 4.4.2. Current GDP Projection and Probable Impact 4.4.3. Current Economic Projection as Compared to 2008 Economic analysis 4.4.4. COVID19 and Impact Analysis 4.4.4.1. Revenue By Offering 4.4.4.2. Revenue By Technology 4.4.4.3. Revenue By Test Type 4.4.4.4. Revenue By Disease 4.4.4.5. Revenue By End User 4.4.4.6. Revenue By Country 4.4.5. 2020 Market Scenario 4.4.6. Quarter by Quarter Forecast 4.4.7. Projected Recovery Quarter 4.4.8. Recovery Scenario – Short term, Midterm and Long Term Impact 5. Market Context 5.1. Adoption and Usage Analysis 5.2. Market Evolution 5.3. Product Vs Technology Matrix 5.4. Regulatory Scenario 5.5. Parent Market Analysis 5.6. Key Promotional Strategies by Market Players 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis By Offering 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Offering 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Offering, 2018 to 2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Offering, 2023 to 2033 8.3.1. Consumables 8.3.2. Instruments 8.3.3. Services 8.4. Market Attractiveness Analysis By Offering 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Test Type 9.1. Introduction / Key Findings Test Type Size, 2018 to 2022 9.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Test Type, 2023 to 2033 9.2.1. Antioxidant Capacity Assays 9.2.2. Ascorbic Acid Assays 9.2.3. Glutathione Assays 9.2.4. Cell-based Exogenous Antioxidant Assays 9.2.5. Indirect Assays 9.2.6. Lipid-based Assays 9.2.7. Nucleic Acid-based Assays 9.2.8. Protein-based Assays 9.2.9. Enzyme-based Assays 9.2.10. Reactive Oxygen Species-based Assays 9.3. Market Attractiveness Analysis By Test Type 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Technology 10.1. Introduction / Key Findings Technology Disease, 2018 to 2022 10.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Technology, 2023 to 2033 10.2.1. ELISA 10.2.2. Chromatography 10.2.3. Flow Cytometry 10.2.4. Microscopy, 10.2.5. High-content Screening 10.2.6. Label-free Detection 10.3. Market Attractiveness Analysis By Technology 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Disease 11.1. Introduction / Key Findings Size, 2018 to 2022 11.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease, 2023 to 2033 11.2.1. Cardiovascular Diseases 11.2.2. Diabetes 11.2.3. Respiratory Diseases 11.2.4. Cancer 11.2.5. Asthma 11.3. Market Attractiveness Analysis By Disease 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by End User 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By End User, 2018 to 2022 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2023 to 2033 12.3.1. Pharma & Biotech Companies 12.3.2. Academic Research Institutes 12.3.3. Clinical Laboratories 12.3.4. Contract Research Organizations 12.4. Market Attractiveness Analysis By End User 13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2018 to 2022 13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. United States 14.3.1.2. Canada 14.3.2. By Offering 14.3.3. By Test Type 14.3.4. By Technology 14.3.5. By Disease 14.3.6. By End User 14.4. Market Attractiveness Analysis 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. Rest of Europe 15.3.2. By Offering 15.3.3. By Test Type 15.3.4. By Technology 15.3.5. By Disease 15.3.6. By End User 15.4. Market Attractiveness Analysis 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. South Africa 16.3.1.3. Rest of Middle East and Africa 16.3.2. By Offering 16.3.3. By Test Type 16.3.4. By Technology 16.3.5. By Disease 16.3.6. By End User 16.4. Market Attractiveness Analysis 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. Rest of the World Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Offering 17.3.2. By Test Type 17.3.3. By Technology 17.3.4. By Disease 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. Key and Emerging Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. United States Market Analysis 18.2.1. By Offering 18.2.2. By Test Type 18.2.3. By Technology 18.2.4. By Disease 18.2.5. By End User 18.3. Canada Market Analysis 18.3.1. By Offering 18.3.2. By Test Type 18.3.3. By Technology 18.3.4. By Disease 18.3.5. By End User 18.4. United Kingdom Market Analysis 18.4.1. By Offering 18.4.2. By Test Type 18.4.3. By Technology 18.4.4. By Disease 18.4.5. By End User 18.5. Germany Market Analysis 18.5.1. By Offering 18.5.2. By Test Type 18.5.3. By Technology 18.5.4. By Disease 18.5.5. By End User 18.6. France Market Analysis 18.6.1. By Offering 18.6.2. By Test Type 18.6.3. By Technology 18.6.4. By Disease 18.6.5. By End User 18.7. Italy Market Analysis 18.7.1. By Offering 18.7.2. By Test Type 18.7.3. By Technology 18.7.4. By Disease 18.7.5. By End User 18.8. Spain Market Analysis 18.8.1. By Offering 18.8.2. By Test Type 18.8.3. By Technology 18.8.4. By Disease 18.8.5. By End User 18.8.6. By End User 18.9. GCC Countries Market Analysis 18.9.1. By Offering 18.9.2. By Test Type 18.9.3. By Technology 18.9.4. By Disease 18.9.5. By End User 18.10. South Africa Market Analysis 18.10.1. By Offering 18.10.2. By Test Type 18.10.3. By Technology 18.10.4. By Disease 18.10.5. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Product foot print by Players 19.4.3. Channel Foot Print by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Abcam PLC 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Analyst Commentary 20.3.1.4. Key Financials 20.3.1.5. Recent Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Strategy 20.3.1.7.3. Channel Strategy 20.3.2. AMS Biotechnology (Europe) Ltd. (AMSBIO) 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Analyst Commentary 20.3.2.4. Key Financials 20.3.2.5. Recent Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Biovision Inc. 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Analyst Commentary 20.3.3.4. Key Financials 20.3.3.5. Recent Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Cell Biolabs, Inc. 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Analyst Commentary 20.3.4.4. Key Financials 20.3.4.5. Recent Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Enzo Biochem, Inc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Analyst Commentary 20.3.5.4. Key Financials 20.3.5.5. Recent Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Merck KgaA 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Analyst Commentary 20.3.6.4. Key Financials 20.3.6.5. Recent Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Strategy 20.3.6.7.3. Channel Strategy 20.3.7. MilliporeSigma 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Analyst Commentary 20.3.7.4. Key Financials 20.3.7.5. Recent Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Oxford Biomedical Research, Inc. 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Analyst Commentary 20.3.8.4. Key Financials 20.3.8.5. Recent Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Promega Corporation 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Analyst Commentary 20.3.9.4. Key Financials 20.3.9.5. Recent Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Strategy 20.3.9.7.3. Channel Strategy 20.3.10. Qiagen NV 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Analyst Commentary 20.3.10.4. Key Financials 20.3.10.5. Recent Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Product Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Thermo Fisher Scientific, Inc. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Analyst Commentary 20.3.11.4. Key Financials 20.3.11.5. Recent Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Product Strategy 20.3.11.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Offering
Table 02: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
Table 03: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
Table 04: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 05: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 06: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Age Group
Table 07: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 08: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 09: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Offering
Table 10: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
Table 11: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
Table 12: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 13: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Offering
Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
Table 17: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
Table 18: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 19: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 20: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 21: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Offering
Table 22: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
Table 23: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
Table 24: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 25: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
Table 26: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Offering
Table 27: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
Table 28: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
Table 29: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease
Table 30: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 02: Global Market Absolute $ Opportunity, 2023 to 2033
Figure 03: Global Market Share Analysis (%), By Offering, 2023 & 2033
Figure 04: Global Market Y-o-Y Analysis (%), By Offering, 2023 to 2033
Figure 05: Global Market Attractiveness Analysis By Offering, 2023 to 2033
Figure 06: Global Market Share Analysis (%), By Test Type, 2023 & 2033
Figure 07: Global Market Y-o-Y Analysis (%), By Test Type, 2023 to 2033
Figure 08: Global Market Attractiveness Analysis By Test Type, 2023 to 2033
Figure 09: Global Market Share Analysis (%), By Technology, 2023 & 2033
Figure 10: Global Market Y-o-Y Analysis (%), By Technology, 2023 to 2033
Figure 11: Global Market Attractiveness Analysis By Technology, 2023 to 2033
Figure 12: Global Market Share Analysis (%), By Disease, 2023 & 2033
Figure 13: Global Market Y-o-Y Analysis (%), By Disease, 2023 to 2033
Figure 14: Global Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 15: Global Market Share Analysis (%), By End User, 2023 & 2033
Figure 16: Global Market Y-o-Y Analysis (%), By End User , 2023 to 2033
Figure 17: Global Market Attractiveness Analysis, By End User, 2023 to 2033
Figure 18: Global Market Share Analysis (%), By Disease Age Group, 2023 & 2033
Figure 19: Global Market Y-o-Y Analysis (%), By Disease Age Group, 2023 to 2033
Figure 20: Global Market Attractiveness Analysis By Disease Age Group, 2023 to 2033
Figure 21: Global Market Share Analysis (%), By Region, 2023 & 2033
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2023 to 2033
Figure 23: Global Market Attractiveness Analysis, By Region, 2023 to 2033
Figure 24: North America Market Value Share, By Offering, 2023 (E)
Figure 25: North America Market Value Share, By Technologys 2023 (E)
Figure 26: North America Market Value Share, By Test Type, 2023 (E)
Figure 27: North America Market Value Share, By Disease, 2023 (E)
Figure 28: North America Market Value Share, By End User, 2023 (E)
Figure 29: North America Market Value Share, By Country, 2023 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 31: North America Market Attractiveness Analysis By Offering, 2023 to 2033
Figure 32: North America Market Attractiveness Analysis By Technology, 2023 to 2033
Figure 33: North America Market Attractiveness Analysis By Test Type, 2023 to 2033
Figure 34: North America Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 35: North America Market Attractiveness Analysis By End User, 2023 to 2033
Figure 36: North America Market Attractiveness Analysis By Country, 2023 to 2033
Figure 37: Europe Market Value Share, By Offering, 2023 (E)
Figure 38: Europe Market Value Share, By Technologys 2023 (E)
Figure 39: Europe Market Value Share, By Test Type, 2023 (E)
Figure 40: Europe Market Value Share, By Disease, 2023 (E)
Figure 41: Europe Market Value Share, By End User, 2023 (E)
Figure 42: Europe Market Value Share, By Country, 2023 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 44: Europe Market Attractiveness Analysis By Offering, 2023 to 2033
Figure 45: Europe Market Attractiveness Analysis By Technology, 2023 to 2033
Figure 46: Europe Market Attractiveness Analysis By Test Type, 2023 to 2033
Figure 47: Europe Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 48: Europe Market Attractiveness Analysis By Test Type, 2023 to 2033
Figure 49: Europe Market Attractiveness Analysis By Country, 2023 to 2033
Figure 50: Middle East and Africa Market Value Share, By Offering, 2023 (E)
Figure 51: Middle East and Africa Market Value Share, By Technology, 2023 (E)
Figure 52: Middle East and Africa Market Value Share, By Test Type, 2023 (E)
Figure 53: Middle East and Africa Market Value Share, By Disease, 2023 (E)
Figure 54: Middle East and Africa Market Value Share, By End User, 2023 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2023 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 57: Middle East and Africa Market Attractiveness Analysis By Offering, 2023 to 2033
Figure 58: Middle East and Africa Market Attractiveness Analysis By Technology, 2023 to 2033
Figure 59: Middle East and Africa Market Attractiveness Analysis By Test Type, 2023 to 2033
Figure 60: Middle East and Africa Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 61: Middle East and Africa Market Attractiveness Analysis By End User, 2023 to 2033
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2023 to 2033
Figure 63: Rest of the World Market Value Share, By Offering, 2023 (E)
Figure 64: Rest of the World Market Value Share, By Technologys 2023 (E)
Figure 65: Rest of the World Market Value Share, By Test Type, 2023 (E)
Figure 66: Rest of the World Market Value Share, By Disease, 2023 (E)
Figure 67: Rest of the World Market Value Share, By End User, 2023 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 69: Rest of the World Market Attractiveness Analysis By Offering, 2023 to 2033
Figure 70: Rest of the World Market Attractiveness Analysis By Technology, 2023 to 2033
Figure 71: Rest of the World Market Attractiveness Analysis By Test Type, 2023 to 2033
Figure 72: Rest of the World Market Attractiveness Analysis By Disease, 2023 to 2033
Figure 73: Rest of the World Market Attractiveness Analysis By End User, 2023 to 2033
Figure 74: United States Market Value Share, By Offering, 2023 & 2033
Figure 75: United States Market Value Share, By Technology, 2023 & 2033
Figure 76: United States Market Value Share, By Test Type, 2020 &2030
Figure 77: United States Market Value Share, By Disease Age Group, 2023 & 2033
Figure 78: United States Market Value Share, By End User, 2023 & 2033
Figure 79: United States Market Value Analysis (US$ Mn), 2023 & 2033
Figure 80: Canada Market Value Share, By Offering, 2023 & 2033
Figure 81: Canada Market Value Share, By Technology, 2023 & 2033
Figure 82: Canada Market Value Share, By Test Type, 2023 & 2033
Figure 83: Canada Market Value Share, By Disease Age Group, 2023 & 2033
Figure 84: Canada Market Value Share, By End User, 2023 & 2033
Figure 85: Canada Market Value Analysis (US$ Mn), 2023 & 2033
Figure 86: United Kingdom Market Value Share, By Offering, 2023 & 2033
Figure 87: United Kingdom Market Value Share, By Technology, 2023 & 2033
Figure 88: United Kingdom Market Value Share, By Test Type, 2023 & 2033
Figure 89: United Kingdom Market Value Share, By Disease Age Group, 2023 & 2033
Figure 90: United Kingdom Market Value Share, By End User, 2023 & 2033
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2023 & 2033
Figure 92: Germany Market Value Share, By Offering, 2023 & 2033
Figure 93: Germany Market Value Share, By Technology, 2023 & 2033
Figure 94: Germany Market Value Share, By Test Type, 2023 & 2033
Figure 95: Germany Market Value Share, By Disease Age Group, 2023 & 2033
Figure 96: Germany Market Value Share, By End User, 2023 & 2033
Figure 97: Germany Market Value Analysis (US$ Mn), 2023 & 2033
Figure 98: France Market Value Share, By Offering, 2023 & 2033
Figure 99: France Market Value Share, By Technology, 2023 & 2033
Figure 100: France Market Value Share, By Test Type, 2023 & 2033
Figure 101: France Market Value Share, By Disease Age Group, 2023 & 2033
Figure 102: France Market Value Share, By End User, 2023 & 2033
Figure 103: France Market Value Analysis (US$ Mn), 2023 & 2033
Figure 104: Italy Market Value Share, By Offering, 2023 & 2033
Figure 105: Italy Market Value Share, By Technology, 2023 & 2033
Figure 106: Italy Market Value Share, By Test Type, 2023 & 2033
Figure 107: Italy Market Value Share, By Disease Age Group, 2023 & 2033
Figure 108: Italy Market Value Share, By End User, 2023 & 2033
Figure 109: Italy Market Value Analysis (US$ Mn), 2023 & 2033
Figure 110: Spain Market Value Share, By Offering, 2023 & 2033
Figure 111: Spain Market Value Share, By Technology, 2023 & 2033
Figure 112: Spain Market Value Share, By Test Type, 2023 & 2033
Figure 113: Spain Market Value Share, By Disease Age Group, 2023 & 2033
Figure 114: Spain Market Value Share, By End User, 2023 & 2033
Figure 115: Spain Market Value Analysis (US$ Mn), 2023 & 2033
Figure 116: GCC Countries. Market Value Share, By Offering, 2023 & 2033
Figure 117: GCC Countries Market Value Share, By Technology, 2023 & 2033
Figure 118: GCC Countries Market Value Share, By Test Type, 2023 & 2033
Figure 119: GCC Countries Market Value Share, By Disease, 2023 & 2033
Figure 120: GCC Countries Market Value Share, By End User, 2023 & 2033
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2023 & 2033
Figure 122: South Africa Market Value Share, By Offering, 2023 & 2033
Figure 123: South Africa Market Value Share, By Technology, 2023 & 2033
Figure 124: South Africa Market Value Share, By Test Type, 2023 & 2033
Figure 125: South Africa Market Value Share, By Disease Age Group, 2023 & 2033
Figure 126: South Africa Market Value Share, By End User, 2023 & 2033
Figure 127: South Africa Market Value Analysis (US$ Mn), 2023 & 2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the market value of oxidative stress assays in 2023?
The global oxidative stress assays market is valued at US$ 1.05 billion in 2023.
What is the projected market value for oxidative stress assays by 2033?
Sales of oxidative stress assays are expected to reach US$ 2.49 billion by 2033.
What is the estimated growth rate for the oxidative stress assays market?
Global demand for oxidative stress assays is predicted to increase at a CAGR of 9% from 2023 to 2033.
Who is the major end user in the oxidative stress assays market?
Biotech and pharma companies are significant users of oxidative stress assays.
Who are the leading players in the oxidative stress assays market?
Thermo Fisher Scientific, Inc., Merck KGaA, and AMS Biotechnology, Ltd. are some of the leading oxidative stress assay-providing companies.
Oxidative Stress Assays Market